نتایج جستجو برای: آنتیبادی مونوکلونال trastuzumab
تعداد نتایج: 9324 فیلتر نتایج به سال:
pr81 آنتی بادی مونوکلونالی است که با افینیتی بالا به muc1 که در سرطان های سینه و سایر سرطان ها بیان بالایی دارد متصل می شود. هدف از این مطالعه مقایسه دو روش نشاندارسازی (مستقیم و غیرمستقیم) برای کاربرد این آنتی بادی ضد muc1 به عنوان یک رادیودارو می باشد. آنتی بادی مونوکلونال pr81 که بر علیه توالی تکراری پروتئین muc1 بود تهیه شده، تعیین ویژگی شده، تخلیص شده و با 131i به دو صورت مستقیم (با استفاد...
میکروارگانیسم های بیماری زا از عوامل اصلی تلفات و خسارت های اقتصادی در صنعت طیور هستند. به دلیل تأثیر این عوامل بر صنعت طیور کیت های آزمایشگاهی مختلفی بر پایه الیزا برای تشخیص عفونت های حاصل از این عوامل طراحی شده اند. در این کیت ها اغلب از یک آنتی بادی ثانویه ی کانژوگه شده با آنزیم به منظور شناسایی igg مرغ استفاده می شود. هدف از مطالعه ی حاضر نشان دار کردن یک آنتی بادی مونوکلونال ضد igg مرغ با...
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by trastuzumab is mostly reversible, some patients, especially those with cardiac risk factors, may rare...
BACKGROUND Cardiotoxicity is an important side effect of trastuzumab therapy and cardiac surveillance is recommended. OBJECTIVES The aim of our study was to prospectively assess baseline patients' characteristics, level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and echocardiographic parameters as possible predictors of trastuzumab-related cardiac dysfunction. METHODS In a pros...
Although the recently concluded CLEOPATRA trial showed clinical benefits of combining trastuzumab and pertuzumab for treating HER2-positive metastatic breast cancer, trastuzumab monotherapy is still the mainstay in adjuvant settings. Since trastuzumab resistance occurs in over half of these cancers, we examined the mechanisms by which treatment of intrinsically trastuzumab-resistant and -sensit...
The anti-ErbB2 antibody trastuzumab is used for the treatment of patients with advanced breast cancer, resulting in a response rate of 40-60%. Coupling with a cytotoxic nuclide, e.g. ·-emitting 211At, may further increase tumour response. The tumour-targeting properties of trastuzumab, astatinated using N-succinimidyl-para-(tri-nmethylstannyl)-benzoate, were evaluated and compared with those of...
Indication for the use of trastuzumab was given in Italy in 2000 for the treatment of HER-2 metastatic breast cancer and in 2006 for early stage breast cancer. Information on trastuzumab use and on its possible variation with age in Italy is however limited. Using health care administrative databases, we evaluated the prevalence of the use of trastuzumab, and the probability for administration ...
Although Trastuzumab, an anti-HER2 antibody, benefits certain patients with HER2-overexpressing breast cancer, de novo or acquired trastuzumab resistance remains a haunting issue. EGFRvIII, co-expressing with HER2 in some breast tumors, indicates a poor clinical prognosis. However, the role of EGFRvIII in the function of trastuzumab is not clear. Here, we demonstrated that EGFRvIII overexpressi...
Breast cancer positive for HER2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of care for early-stage patients with HER2-positive breast cancer. In that population, trastuzumab has been studied in six randomized clinical ...
The humanized monoclonal antibody trastuzumab has been in routine use for chemotherapy for human epidermal growth factor receptor II (HER2)-positive breast cancer. A major adverse effect of trastuzumab is cardiotoxicity. Well-established biomarkers or echocardiographic parameters to predict trastuzumab-induced cardiotoxicity have not yet been determined. We attempted to identify useful biomarke...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید